Long-term follow-up of ALXN2220 in adults with transthyretin amyloid heart disease
Continues ALXN2220 treatment in adults with transthyretin amyloid cardiomyopathy who finished an earlier study.
Plain-language title generated from the registry record
Registry title: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
Key facts
- Where
- Calgary, Chicoutimi, London, Montr Al, Rimouski, and Winnipeg, CanadaSee the 6 sites
- Phase
- Phase 3
Where in Canada
- CalgaryCalgary, CanadaNo longer taking part
- ChicoutimiChicoutimi, CanadaNo longer taking part
- LondonLondon, CanadaNo longer taking part
- Montr AlMontr Al, CanadaNo longer taking part
- RimouskiRimouski, CanadaNo longer taking part
- WinnipegWinnipeg, CanadaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Alexion Pharmaceuticals, Inc.
- Trial code
- NCT07789483EU 2026-526755-57-00
- Record updated
- 28 August 2026
- Original description
The purpose of Study ALXN2220-ATTRCM-302 is to evaluate the long-term safety, tolerability and efficacy of ALXN2220 in adult participants with ATTR-CM treated with ALXN2220 in addition to SoC who have completed Study ALXN2220-ATTRCM-301.Read full original descriptionShow less
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of ALXN2220 in Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
The purpose of Study ALXN2220-ATTRCM-302 is to evaluate the long-term safety, tolerability and efficacy of ALXN2220 in adult participants with ATTR-CM treated with ALXN2220 in addition to SoC who have completed Study ALXN2220-ATTRCM-301.
Inclusion Criteria; Type of Participant: Participants who have completed the Blinded Treatment Period (including the PC visit) of Study 301; Sex and Contraceptive/Barrier Requirements: Male and/or female (according to their reproductive organs and functions assigned by chromosomal complement); Informed Consent: Participant, or legally authorized representative where relevant and allowed by law, is willing and able to comply with all study requirements and to provide signed informed consent; Exclusion Criteria; Participants who permanently discontinued study intervention in Study 301; Participants who withdrew full consent during Study 301; Medical Conditions: Suspected or known intolerance/allergy to proteins or any components of ALXN2220. Has had a heart transplant or permanent CMAD implantation. Has any new or worsening of existing medical or psychological condition or risk factor that in the opinion of the Investigator or Sponsor might jeopardize participant's safety or compliance with the protocol, or pose any additional risk for the participant, or confound the assessment of the participant or outcome of the study; Prior/Concurrent/Future Clinical Study Experience: Current or future participation in another investigational clinical study or intake of investigational drug within 30 calendar days or 5 half-lives of the study intervention, whichever is longer, before signing the ICF, except for study intervention used in Study 301.